***Background.*** Allogeneic hematopoietic stem cell transplantation (SCT) is often used as definitive therapy for hemophagocytic lymphohistiocytosis (HLH). Data on infectious complications in post-SCT HLH patients are limited, with no analyses comparing their infectious risk to other SCT recipients. This study compares post-SCT infection frequency and mortality rates between pediatric HLH and leukemia patients.

***Methods.*** All HLH SCT patients from 1997 to 2009 were identified from the bone marrow registry at The Children\'s Hospital of Philadelphia. HLH patients were matched one-to-one to leukemia SCT patients by age and transplant year. Data on demographics, donor source, conditioning regimens, microbiologically-proven infections, and vital status 6 months post-SCT were collected. Multivariate conditional Poisson and logistic/Cox regression models compared infection rate per follow-up days and mortality, respectively.

***Results.*** Eighteen HLH SCT patients (100%) had at least one infection, (median: 2; IQR: 1 to 4). Half of the leukemia SCT recipients had at least 1 infection (median: 1; IQR: 0 to 2). Compared to leukemia patients, HLH patients had a greater incidence of total infections (IRR: 2.47, 95% CI: 1.01 to 6.05; table). After adjusting for sex, conditioning regimen, and antithymocyte or antilymphocyte globulin (ATG/ALG) use, this difference was no longer significant (IRR: 1.69, 95% CI: 0.72 to 3.95). Receipt of ATG/ALG was independently associated with a greater infection rate (IRR: 2.30, 95% CI: 1.10 to 4.81). Mortality rate (HLH 22%, leukemia 28%) and time to death post-SCT did not differ between groups.

###### 

Microbiologically Proven Infection

                   [HLH]{.ul}   [Leukemia]{.ul}
  ---------------- ------------ -----------------
  **Bacteremia**                
  Gram Positive    14 (42)      5 (35)
  Gram Negative    2 (6)        6 (42)
  **Candidemia**   2 (6)        0
  **Viral**                     
  Respiratory      9 (27)       2 (14)
  Reactivation     6 (18)       1 (7)

***Conclusion.*** HLH SCT recipients have a higher infection rate in the 6 months post-HSCT compared to leukemia patients, a factor associated with pre-transplant ATG/ALG use. It is possible a difference in mortality and infection rates exists beyond the variation in ATG/ALG exposure. Further study of larger cohorts is needed.
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